Table 4.
Adjusted differences to event-free survival among patients with < 2 g, 2 to 3 g, and > 3 g of dietary sodium intake in NYHA class I/II and NYHA class III/IV
| N = 244 | |||||||
|---|---|---|---|---|---|---|---|
| Variables | NYHA class I/II (n = 134) |
NYHA class III/IV (n = 110) |
|||||
| Adjusted HR |
95% CI | p | Adjusted HR |
95% CI | p | ||
| Age (years) | 1.00 | 0.97 – 1.03 | .996 | 1.00 | 0.97 – 1.02 | .712 | |
| Female gender | 0.32 | 0.13 – 0.83 | .018 | 1.41 | 0.66 – 3.00 | .381 | |
| BMI (kg/m2) | 1.03 | 0.95 – 1.11 | .515 | 1.02 | 0.98 – 1.06 | .408 | |
| Ischemic heart disease | 1.43 | 0.58 – 3.53 | .436 | 0.99 | 0.52 – 1.94 | .998 | |
| Preserved LVEF ≥ 40% | 0.92 | 0.38 – 2.26 | .860 | 0.53 | 0.25 – 1.22 | .093 | |
| Total comorbidity | 0.79 | 0.60 – 1.04 | .095 | 1.13 | 0.98 – 1.30 | .089 | |
| ACE inhibitors | 1.07 | 0.45 – 2.53 | .878 | 1.04 | 0.54 – 1.99 | .907 | |
| Diuretics | 1.95 | 0.72 – 5.32 | .190 | 1.07 | 0.49 – 2.36 | .868 | |
| Beta blockers | 0.82 | 0.29 – 2.31 | .702 | 1.90 | 0.85 – 4.24 | .118 | |
| Total energy (Kcal) | 1.00 | 0.99 – 1.00 | .352 | 0.98 | 0.96 – 1.01 | .114 | |
| Lower leg or ankle edema | 0.63 | 0.24 – 1.62 | .333 | 1.26 | 0.50 – 3.17 | .626 | |
| 2g–3g/day of sodium intake | 1.00 | 1.00 | |||||
| < 2g/day of sodium intake | 3.68 | 1.18–11.50 | .025 | 0.65 | 0.23 – 1.83 | .418 | |
| > 3g/day of sodium intake | 0.39 | 0.16 – 0.98 | .047 | 2.06 | 1.02 – 4.17 | .044 | |
ACE; angiotensin-converting enzyme, BMI; body mass index, HR; hazard ratio, LVEF; left ventricular ejection fraction, NYHA; New York Heart Association